BRUNNUR-VENTURES-GP
Brunnur Ventures GP (www.brunnurventures.com ) is pleased to announce the launch of Brunnur II, its second venture fund of US$65 million (ISK 8.3 billion). The new fund's Limited Partners include ten of Iceland’s leading pension funds and Landsbanki.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210315005857/en/
Brunnur II is a lead investor targeting seed and early-stage investments in Iceland with a focus on start-up companies with extraordinary entrepreneurial talent, innovative, high-growth and scalable business models. The fund’s sector focus is primarily within software/IT, gaming, Industry 4.0, biotech, cleantech, marine tech, agrifoodtech and other high technology sectors that have a competitive edge through patentable technology or proprietary know-how.
“We are delighted to be announcing the close of Brunnur II and our enlarged team which brings together a real concentration of expertise in seeking out, participating in and driving the growth of the most promising and scalable start-ups,” commented Arni Blondal, Managing Partner of Brunnur Ventures GP. “We are continuing a strategy of catalyzing the growth and internationalization of our portfolio companies through leveraging our hands-on start-up experience and network. I am also pleased to welcome our two new Partners, Margret O. Asgeirsdóttir and Kjartan Olafsson, who bring a wealth of additional expertise to further guide the leadership of our portfolio.”
Brunnur Ventures GP debut fund, Brunnur I, a 2015 vintage, has invested in a range of exciting companies that include Oculis, DT Equipment, Grid, Laki Power, Nanitor, IMS and Avo Software. Brunnur Ventures' co-investors include Earlybird, NEA, Chrysalix, Blue Yard, GGV Capital, Y Combinator, Novartis Venture Fund and others.
Brunnur II intends to invest in a portfolio of up to 20 companies with initial investments ranging from US$ 1-3 million, with capital pre-allocated for follow on investments.
ABOUT BRUNNUR VENTURES
Brunnur Ventures is venture capital firm based in Iceland focused on seed and early-stage investments, emphasizing innovation and growth, combined with scalable business models and extraordinary entrepreneurial talent.
Brunnur Ventures currently manages two funds, Brunnur I and Brunnur II, with fund operation and administration provided by Landsbref (www.landsbref.is ), a fund management company licensed by the Icelandic Financial Supervisory Authority.
For more information please visit: www.brunnurventures.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005857/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Partners Sends Second Public Shareholder Letter to Coway, Urging Announcement of Revised Value-up Plan by January 30, 202615.12.2025 15:54:00 CET | Press release
Align identifies an inefficient capital structure and a sharp contraction in shareholder returns as core drivers of Coway’s undervaluationThe letter outlines seven key measures to strengthen capital allocation and governanceAlign urges Coway to announce a more concrete and enhanced Value-up Plan by January 30, 2026 Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Coway Co., Ltd. (“Coway”) since 2023 holding more than 4% of the Company’s outstanding shares through funds it manages or advises, announced that it has sent a second public shareholder letter to Coway’s Board of Directors. The letter calls for measures to address the company’s chronic undervaluation and enhance shareholder value. Align Partners has requested that Coway announce a revised corporate Value-up Plan reflecting these proposals by January 30, 2026. In the letter, Align Partners assessed Coway’s February 2025 plan as insufficient to address Coway’s persistent undervaluation and urged the Bo
Marathon Asset Management Provides Junior Capital Financing to EXALTA Group15.12.2025 15:00:00 CET | Press release
Marathon Asset Management (“Marathon”), a leading global credit manager with more than $24 billion of assets under management, is pleased to announce the closing of a junior capital financing to EXALTA Group (“EXALTA” or the “Company”), a portfolio company of Montagu. Marathon led the financing that supported the formation of EXALTA through the strategic merger of three Montagu-owned companies including Intech, Resolve Surgical Technologies, and Tyber Medical. The transaction marks one of many successful transactions for Marathon’s European Credit business in the healthcare sector, where the firm has a knowledge-based advantage with a dedicated Healthcare Finance business and specialized medical advisory board providing sector insight to middle market companies. EXALTA is a global leader in orthopaedic contract design and manufacturing for spine, trauma, extremities, sports medicine and enabling technology providing comprehensive solutions to OEMs within the medical technology industry
Aurobay Technologies Expands Digital Transformation Partnership With HCLTech to Boost Manufacturing Excellence and Innovation15.12.2025 14:29:00 CET | Press release
HCLTech, a leading global technology company, and Aurobay Technologies, a division of Horse Powertrain and a global leader in hybrid and low-emission powertrain solutions, have expanded their digital transformation partnership to support Aurobay’s global growth strategy. The expanded partnership establishes HCLTech as Aurobay Technologies’ trusted partner for managing and optimizing SAP, Siemens Teamcenter PLM software and integration services in Sweden and China. This will unlock cost efficiency, operational resilience and digital innovation across Aurobay’s manufacturing and engineering functions by leveraging HCLTech’s flagship service transformation platform, AI Force. The engagement spans core business functions including SAP operations, engineering systems, integration services and mainframe environments, reinforcing Aurobay’s focus on scale, efficiency and seamless operations across global locations. “Horse Powertrain’s division Aurobay Technologies’ digital transformation conti
Applications Now Open for the 5th Cycle of the Mohammed bin Rashid Al Maktoum Global Water Award15.12.2025 14:28:00 CET | Press release
HE Saeed Mohammed Al Tayer, Chairman of the Board of Trustees of the UAE Water Aid Foundation (Suqia UAE), announced the opening of applications for the 5th cycle of the Mohammed bin Rashid Al Maktoum Global Water Award, offering USD 1 million in prizes. The award seeks to inspire innovative, clean energy–powered solutions for water production, distribution, storage, desalination and purification, supporting global sustainability efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215897854/en/ HE Saeed Mohammed Al Tayer, Chairman of the Board of Trustees of the UAE Water Aid Foundation (Suqia UAE) - (Photo: AETOSWire) “Since its establishment, Suqia UAE, launched by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, has provided clean water to nearly 15 million people in 37 countries worldwide through sustainable development and humanitarian projects.
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution15.12.2025 14:05:00 CET | Press release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I to Phase II, but only 3–6% reaching regulatory approval, the paper outlines the factors influencing early-stage success, including trial design, patient selection, and regional development pathways. The paper highlights Australia’s continued position as a global first-in-human (FIH) and early-phase research hub. Its ethics-led review frameworks, which can support trial initiation within roughly 4–8 weeks, combined with established FIH centers, oncology networks, and cost efficiencies, position Au
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom